

Drug Monograph

Drug Name: **Loreev XR™ (lorazepam) capsule**
 Drug Class: **Central Nervous System: Benzodiazepines**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Loreev XR is available in 1 mg, 2 mg, and 3 mg extended-release capsules.

Manufacturer: Distributed by: Almatica Pharma LLC, Morristown, NJ 07960.

Indications: Loreev XR is indicated for the treatment of anxiety disorders in adults who are receiving stable, evenly divided, three times daily dosing with lorazepam tablets.

Costs: \$285 for 30 tablets of Loreev XR Wholesale Acquisition Cost

Summary of Findings: The MO Healthnet Division recommends adding this drug to the current High Risk Therapies Clinical Edit, the Benzodiazepines (Select Oral) Clinical Edit and the Polypharmacy Clinical Edit.

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: April Ash, PharmD
 Date: September 29, 2021